Acadia Beats Q3 Estimates, Guides Revenue Higher

Finance teams tracking biopharma peers can use Acadia's quarterly beat and $1.26B-$1.3B guidance as a benchmark for growth expectations.

Updated on Nov. 4, 2026 in Corporate Finance

Acadia Beats Q3 Estimates, Guides Revenue Higher

Acadia Pharmaceuticals Inc., based in San Diego, reported third-quarter net income of $53.5 million, or 31 cents per share, and revenue of $342.3 million. The company also expects full-year revenue of $1.26 billion to $1.3 billion, a range relevant to investors and corporate finance teams tracking biopharma performance.

Why it matters

Both the quarterly results and the full-year guidance beat the Zacks analyst average estimates of 19 cents per share and $334.9 million in revenue, a signal of how the market is pricing growth expectations for mid-cap drug developers. Investor sentiment has nonetheless been weak, with shares down 20% since the beginning of 2026.

Acadia's third-quarter net income of $53.5 million and revenue of $342.3 million both topped Zacks analyst averages of 19 cents per share and $334.9 million. The company's full-year revenue guidance of $1.26 billion to $1.3 billion provides a benchmark for the year ahead, though the source does not detail the underlying product mix driving it.

The players

Acadia Pharmaceuticals Inc.

A San Diego-based biopharmaceutical company that develops and commercializes prescription medicines, with a publicly traded stock.

Zacks Investment Research

An independent equity research firm whose consensus analyst estimates serve as a common benchmark for quarterly earnings expectations.

The details

Acadia's results exceeded consensus on both the earnings and top-line measures, which typically reflects stronger-than-expected sales and cost control. The full-year guidance range gives investors and finance teams a forward revenue baseline to weigh against the stock's 20% year-to-date decline. The source does not provide further operational or financial mechanism behind these results.

Third quarter 2026: Acadia reported its quarterly earnings and revenue.
November 4, 2026: Earnings were reported and shares closed near $21.49.
Since the start of 2026: Acadia shares have fallen 20%.

Market Landscape

Results measured against Zacks analyst consensus give investors a standard yardstick for mid-cap biopharma performance. Acadia's beat on both earnings and revenue contrasts with its 20% share decline since the start of 2026, a gap that finance teams tracking public-company valuations will want to monitor.

Finance teams at companies that track biopharma peers should compare Acadia's guidance range against its reported quarterly run-rate when updating internal benchmarks. Operators should consult qualified accountants before making any decisions tied to public-market valuations.

The takeaway

Acadia's beat on both earnings and revenue, paired with a 20% share decline, shows that reported results and market valuation can diverge sharply. Finance leaders should reconcile guidance against quarterly actuals in their next planning cycle and review the decision with a qualified accountant where it affects reporting or valuation.